Bone health is not a topic that features prominently in vaping health discussions, and yet the skeletal system is a genuine target of nicotine’s physiological effects through mechanisms that are well-characterised in orthopaedic and rheumatological research. For the millions of adults who have switched from cigarettes to e-cigarettes — often celebrating the health improvements they notice — understanding whether their new nicotine delivery method continues to affect bone density, fracture healing and skeletal metabolism is an important part of a complete harm reduction picture. Vapers making informed choices about their purchase from any established vape shop should be aware of what the evidence says about nicotine and skeletal health, and what remains genuinely uncertain.
How Smoking Damages Bone: The Baseline
The relationship between smoking and bone health is one of the most robust in the musculoskeletal literature. Smokers have measurably lower bone mineral density (BMD) than non-smokers across all skeletal sites, with the most pronounced differences at the lumbar spine and femoral neck — the two sites most clinically relevant for osteoporotic fracture risk. Meta-analyses consistently show that current smokers have a 25–40% higher risk of hip fracture and a 13% higher risk of vertebral fracture compared to non-smokers, after adjustment for age, sex, body weight and other risk factors.
The mechanisms are multiple. Nicotine impairs bone formation by inhibiting osteoblast (bone-forming cell) differentiation and proliferation while promoting osteoclast (bone-resorbing cell) activity — a combination that shifts the normal bone remodelling balance toward net resorption. Carbon monoxide reduces oxygen delivery to bone tissue, impairing the metabolic processes of osteoblast function. Smoking reduces intestinal calcium absorption through effects on vitamin D metabolism. The combination of these mechanisms produces the sustained bone density deficit seen in long-term smokers.
Nicotine’s Direct Effects on Bone Cells
The separation of nicotine’s specific bone effects from those of cigarette combustion products is important for understanding vaping’s skeletal implications. Nicotinic acetylcholine receptors (nAChRs) are expressed on both osteoblasts and osteoclasts, and nicotine binding to these receptors has direct consequences for bone cell function that are independent of combustion.
In osteoblasts — the cells responsible for synthesising new bone matrix and mineralising it — nicotine at concentrations achievable through regular vaping has been shown in multiple in vitro studies to reduce proliferation, impair alkaline phosphatase activity (a marker of osteoblast maturation), and reduce the expression of osteocalcin and collagen type I — the proteins that form the organic scaffold of bone. These effects are dose-dependent: at concentrations equivalent to light vaping use, the effects are modest; at concentrations equivalent to heavy use, they become more pronounced.
In osteoclasts — the cells that resorb (break down) existing bone — nicotine promotes differentiation and activity through receptor-activator of NF-κB ligand (RANKL) pathway activation. Increased RANKL signalling accelerates osteoclast formation and bone resorption rate. The net result of simultaneously suppressing osteoblast function and stimulating osteoclast activity is a shift in bone remodelling toward resorption — the same direction as in smoking, but potentially at a lower magnitude.
What the Vaping-Specific Evidence Shows
Direct clinical evidence for vaping’s effects on bone density in humans is limited by the relatively recent emergence of vaping as a widespread behaviour — longitudinal DXA (dual-energy X-ray absorptiometry) studies of bone density changes in vapers compared to non-users require years of follow-up and have not yet been published with adequate sample sizes and follow-up duration. The available evidence comes primarily from three sources: in vitro studies of nicotine effects on bone cells (discussed above), animal studies, and the mechanistic extrapolation from smoking research.
Animal studies using nicotine-only delivery (via osmotic pump or drinking water, avoiding combustion) at doses equivalent to moderate human nicotine consumption have consistently demonstrated reduced BMD, impaired bone healing after experimental fractures, and altered bone microarchitecture compared to unexposed controls. A 2021 study in Bone Reports found that rats exposed to e-cigarette aerosol for eight weeks showed measurably lower trabecular bone density and altered bone microstructure compared to air-exposed controls, with effects intermediate between unexposed animals and those exposed to cigarette smoke.
Current scientific position: nicotine-specific effects on bone cells are well-established at the mechanistic level, and animal data suggests that vaping produces bone effects of smaller magnitude than smoking but greater than zero. Human clinical data specifically examining bone density in vapers is limited and awaits longer follow-up studies. The elimination of combustion products in vaping removes some of the additional skeletal insults from smoking (CO-mediated hypoxia, vitamin D metabolism disruption), likely producing a better bone health trajectory than continued smoking.
Fracture Healing: A Critical Clinical Consideration
The clinical context in which nicotine’s bone effects are most acutely relevant is fracture healing — the process by which broken bone repairs itself through a carefully orchestrated sequence of inflammatory, proliferative and remodelling phases that ultimately deposits new bone matrix bridging the fracture gap. This process depends critically on adequate blood supply to the fracture site, robust osteoblast activity, and appropriate inflammatory signalling.
Nicotine impairs fracture healing through all three of these requirements: vasoconstriction reduces blood flow to the fracture haematoma and repair tissue; osteoblast suppression reduces the rate of new bone matrix deposition; and the anti-inflammatory effects of nicotine via the cholinergic pathway (discussed in the companion immune system article) alter the inflammatory phase that normally initiates and coordinates the repair cascade. Orthopaedic surgeons treating fractures in smokers consistently observe delayed union, higher rates of non-union (failure to heal), and more frequent implant failure in surgical fixation compared to non-smokers.
Whether vaping produces clinically significant fracture healing impairment is currently unresolved by clinical trials, but the nicotine-specific mechanisms are present and the preclinical data is consistent with a real but smaller-magnitude effect compared to smoking. Orthopaedic surgeons and trauma specialists are increasingly including vaping in preoperative risk assessments for fracture repair procedures, treating it with similar (if less severe) concern as smoking status.
Populations at Elevated Risk: Who Should Be Most Concerned
While nicotine’s bone effects are relevant to all vapers, certain populations face elevated baseline risk where even modest additional bone density reduction has clinical significance:
- Postmenopausal women: The decline in oestrogen at menopause already produces accelerated bone density loss (typically 1–3% per year in the first few years post-menopause). Any additional nicotine-mediated osteoblast suppression compounds this established risk and may meaningfully increase fracture risk in a population already at elevated baseline risk for osteoporosis.
- Men over 60: Male osteoporosis is underdiagnosed and undertreated relative to female osteoporosis, despite significant prevalence. Nicotine use in older men is an additive risk factor that merits inclusion in bone density screening decisions.
- People with inflammatory arthritis: Conditions including rheumatoid arthritis and psoriatic arthritis are independently associated with accelerated periarticular bone loss through inflammatory mechanisms. Nicotine’s suppression of pro-inflammatory cytokines may partially counteract this specific mechanism, but the systemic bone effects and medication interactions create a complex overall picture.
- Individuals taking glucocorticoids: Long-term steroid therapy is one of the most potent causes of secondary osteoporosis. Nicotine use in patients on chronic steroids represents compounded risk from two independent mechanisms of osteoblast suppression.
- People recovering from fractures or bone surgery: As described above, nicotine impairs fracture healing regardless of delivery method. Active management of nicotine use during the healing period should be part of orthopaedic care planning.
Vitamin D, Calcium and Vaping
Cigarette smoking disrupts vitamin D metabolism through induction of CYP450 enzymes that accelerate the catabolism of 25-hydroxyvitamin D — the circulating storage form of vitamin D used to assess status. This mechanism contributes to the higher rates of vitamin D insufficiency observed in smokers. Vaping, by eliminating the combustion products that induce these CYP enzymes, likely has a smaller effect on vitamin D metabolism. However, vitamin D status should be assessed as part of any bone health evaluation in vapers, particularly those transitioning from long-term smoking where vitamin D insufficiency may have been established by years of tobacco use.
Calcium intake and absorption are less directly affected by nicotine than by smoking, but adequate calcium remains essential for bone health regardless of nicotine status. Irish adults — with relatively low sunlight exposure, moderate dairy consumption patterns, and a high proportion of vitamin D insufficiency in the general population — already face above-average risk for suboptimal bone mineralisation, making attention to calcium and vitamin D status particularly relevant in the Irish vaping population.
Practical Guidance for Vapers Concerned About Bone Health
- If you are over 50, post-menopausal, or have other osteoporosis risk factors, discuss vaping status explicitly with your GP in the context of bone health assessment. DEXA scanning is available through the Irish public health system for higher-risk individuals and provides a baseline against which future changes can be tracked.
- Ensure adequate calcium intake (1,000–1,200 mg daily for adults over 50) through diet and supplementation if needed. Dairy products, fortified plant milks, canned fish with bones, and green leafy vegetables are accessible Irish dietary sources.
- Have vitamin D status checked — a simple blood test — and supplement appropriately if insufficient. The Irish Osteoporosis Society recommends vitamin D supplementation for most Irish adults from October to April given the limited sunshine in winter months.
- Engage in weight-bearing exercise regularly — walking, jogging, resistance training and dancing all generate the mechanical loading signals that stimulate osteoblast activity and maintain bone density. This is the most powerful modifiable bone health intervention available to any adult regardless of nicotine use.
- Progress toward nicotine reduction over time. The bone case for reducing nicotine is one of several system-specific arguments that collectively make progressive reduction a well-supported long-term strategy.